Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial

Table 4 Subanalysis of individuals with TRIM-D compliance score ≥80 at endpoint^a

	U-500R TID (n = 159) n (%)	U-500R BID (n = 153) n (%)	Total (N = 312) n (%)	Odds Ratio U-500R BID/TID	95 % CI of Odds Ratio	p-value
Number of patients with TRIM-D compliance score ≥80	58 (36.5)	75 (49.0)	133 (42.6)	1.70	1.05, 2.75	.03

Abbreviations: BID twice daily; CI confidence interval; n number of patients in a specified group; N total number of patients; TID thrice daily; TRIM-D Treatment Related Impact Measure-Diabetes; U-500R human regular U-500 insulin
^aCI and p-values were from a logistic regression model with fixed effects for treatment, baseline score and baseline stratification variables (Baseline A1C (≤8 % or >8 %), Baseline TDD (≤300 or >300), and pooled investigator). p-value from this analysis was based on a null hypothesis that the odds ratio is one

ISSN: 1477-7525